Invited Editorials

2024

• Akhade A, Verduzco-Aguirre H^#, Gyawali B*. Geriatric oncology in LMICs: it is time to mature. BMJ Oncology. 2024 Aug 12;3(1). PMID: 39886151
  
• Sanford N and Gyawali B*. Financial Conflicts of Interest: Payment at the Expense of Patients?. JCO oncology practice. 2024. PMID: 38498791

2023

• Gyawali B*, Strohbehn GW. Immunotherapy in Prepatients-Preventing or Promoting a Malignant Transformation? JAMA Oncol. PMID: 37971752.

• Booth CM, Sengar M, Goodman A, Wilson B, Aggarwal A, Berry S, Collingridge D, Denburg A, Eisenhauer EA, Ginsburg O, Goldstein D, Gunasekera S, Hammad N, Honda K, Jackson C, Karikios D, Knopf K, Koven R, Marini BL, Maskens D, Moraes FY, Mohyuddin GR, Poudyal BS, Pramesh CS, Roitberg F, Rubagumya F, Schott S, Sirohi B, Soto-Perez-de-Celis E, Sullivan R, Tannock IF, Trapani D, Tregear M, van der Graaf W, Vanderpuye V, and  Gyawali B. Common Sense Oncology: outcomes that matter. Lancet Oncol. 2023 Jul 14. PMID: 37467768.

• Jenei K^#, Gyawali B*. Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting? Healthc Pap. 2023 Jan;21(1):44-51. PMID: 36692916.

2022

• Knopf KB, Gyawali B*. Intention to probe into the colonoscopy trial: Is it the procedure or the trial that failed? EClinicalMedicine. 2022 Dec 24;55:101793. PMID: 36589265

• Gyawali B*. Lessons learned from the accelerated approval of cancer drugs. Clin Adv Hematol Oncol. Clin Adv Hematol Oncol. 2022 Jul;20(7):441-443. PMID: 35802876.

• Aggarwal C and Gyawali B. Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access? J Clin Oncol. 2022. PMID: 35679530.

2021

• Gyawali B* and Booth CM. Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom? ASCO Daily News. November 2021.

• West HJ and Gyawali B. What Is the Least We Should Expect From New Drugs? The Relative Harm of ‘Me-Too’ Drug Approvals. ASCO Daily News.

• West HJ and Gyawali B. Why Not Adore ADAURA?-The Trial We Need vs the Trial We Got. JAMA Oncology 2021. PMID: 33538783

2020

• Wijeratne DT, Hammad N and Gyawali B*. Gender differences in outcomes of cancer patients with COVID: Signal or noise? Eclinicalmedicine. 2020. PMID: 32923994

• Desai A^# and Gyawali B*. Fall in US cancer death rates: Time to pop the champagne?. Eclinicalmedicine, Published by the Lancet. February, 2020. PMID: 32025656.

2019

• Gyawali B*. Multiple approvals, celestial prices, unimproved outcomes: the tale of cost-ineffective drugs in hepatocellular carcinoma. Journal of NCCN. 2019. PMID: 31200350

2018

• Gyawali B* and West J. Plasma vs Tissue Next-Generation Sequencing in Non–Small Cell Lung Cancer—Either, Both, or Neither? JAMA Oncology 2018. PMID: 30325996 Altmetric score: 149

• Gyawali B* and Lopes G. What Global Oncology Needs: More Funding and Mutual Learning. Journal of Global Oncology 2018. PMID: 30241238

2017

• Gyawali B*. Cancer Drugs in LMICs: cheap but unaffordable. Oncotarget. 8; 52 :89425-89426. Oct 27, 2017. (PMID: 29163757)

• Gyawali B*. Biosimilars in Oncology: everybody agrees but nobody uses? Recenti Progressi in Medicina 2017; 108: 173-175  (PMID: 28492585)